(ACRS) Aclaris Therapeutics - Ratings and Ratios
Hair Loss, Skin Lesion, Immune, Oral, Topical
ACRS EPS (Earnings per Share)
ACRS Revenue
Description: ACRS Aclaris Therapeutics
Aclaris Therapeutics Inc (NASDAQ:ACRS) is a US-based pharmaceutical company. As a trading analyst, we need to deconstruct the companys quarterly tax provision to understand its financial health.
The companys market capitalization stands at $177.58M, indicating a relatively small-cap stock. The absence of a price-to-earnings (P/E) ratio and forward P/E ratio suggests that the company is likely loss-making, which is further supported by the negative Return on Equity (RoE) of -95.92%. This implies significant losses, potentially due to high research and development expenses.
Key economic drivers for Aclaris Therapeutics include the development and commercialization of its pharmaceutical products. The companys ability to generate revenue, manage costs, and achieve profitability will be crucial in driving its stock performance. Key Performance Indicators (KPIs) to monitor include revenue growth, R&D expenses as a percentage of revenue, and cash burn rate.
From a trading perspective, the stocks beta of 0.310 indicates relatively low volatility compared to the broader market. However, the Average True Range (ATR) of 0.08 (4.14% of the last price) suggests that the stock still exhibits some price movement. The short-term and long-term moving averages (SMA20, SMA50, and SMA200) can be used to identify trends and potential trading opportunities.
To make informed trading decisions, its essential to analyze the companys quarterly tax provision in the context of its overall financial performance, industry trends, and market conditions. A thorough analysis of the companys cash flow statements, income statements, and balance sheets will provide valuable insights into its financial health and potential future performance.
ACRS Stock Overview
| Market Cap in USD | 223m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2015-10-07 |
ACRS Stock Ratings
| Growth Rating | -39.0% |
| Fundamental | 22.8% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 30.5% |
| Analyst Rating | 4.33 of 5 |
ACRS Dividends
Currently no dividends paidACRS Growth Ratios
| Growth Correlation 3m | 88% |
| Growth Correlation 12m | -11.8% |
| Growth Correlation 5y | -73.1% |
| CAGR 5y | -49.14% |
| CAGR/Max DD 3y | -0.51 |
| CAGR/Mean DD 3y | -0.55 |
| Sharpe Ratio 12m | -0.04 |
| Alpha | 0.20 |
| Beta | 0.672 |
| Volatility | 68.68% |
| Current Volume | 675.4k |
| Average Volume 20d | 743k |
| Stop Loss | 1.6 (-11.6%) |
| Signal | -0.69 |
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-134.7m TTM) > 0 and > 6% of Revenue (6% = 1.01m TTM) |
| FCFTA -0.11 (>2.0%) and ΔFCFTA 38.76pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 460.8% (prev 318.4%; Δ 142.4pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.05 (>3.0%) and CFO -9.99m > Net Income -134.7m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.88 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (122.6m) change vs 12m ago 71.94% (target <= -2.0% for YES) |
| Gross Margin 24.18% (prev 65.56%; Δ -41.39pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 9.59% (prev 19.88%; Δ -10.29pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -13.91 (EBITDA TTM -56.3m / Interest Expense TTM 4.09m) >= 6 (WARN >= 3) |
Altman Z'' -32.65
| (A) 0.41 = (Total Current Assets 104.2m - Total Current Liabilities 26.8m) / Total Assets 189.1m |
| (B) -4.93 = Retained Earnings (Balance) -933.4m / Total Assets 189.1m |
| warn (B) unusual magnitude: -4.93 — check mapping/units |
| (C) -0.33 = EBIT TTM -57.0m / Avg Total Assets 175.1m |
| (D) -16.25 = Book Value of Equity -932.9m / Total Liabilities 57.4m |
| Total Rating: -32.65 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 22.78
| 1. Piotroski 0.50pt = -4.50 |
| 2. FCF Yield -13.08% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.24 = 2.47 |
| 5. Debt/Ebitda -0.55 = -2.50 |
| 6. ROIC - WACC (= -49.30)% = -12.50 |
| 7. RoE -95.92% = -2.50 |
| 8. Rev. Trend -46.31% = -3.47 |
| 9. EPS Trend 15.70% = 0.78 |
What is the price of ACRS shares?
Over the past week, the price has changed by -11.27%, over one month by -2.16%, over three months by +29.29% and over the past year by +54.70%.
Is Aclaris Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ACRS is around 1.29 USD . This means that ACRS is currently overvalued and has a potential downside of -28.73%.
Is ACRS a buy, sell or hold?
- Strong Buy: 3
- Buy: 2
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ACRS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 7.9 | 334.3% |
| Analysts Target Price | 7.9 | 334.3% |
| ValueRay Target Price | 1.5 | -19.9% |
Last update: 2025-09-05 04:30
ACRS Fundamental Data Overview
CCE Cash And Equivalents = 99.8m USD (Cash And Short Term Investments, last quarter)
P/S = 13.2923
P/B = 1.694
P/EG = -0.13
Beta = 0.31
Revenue TTM = 16.8m USD
EBIT TTM = -57.0m USD
EBITDA TTM = -56.3m USD
Long Term Debt = 30.6m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 515.0k USD (from shortTermDebt, last quarter)
Debt = 31.1m USD (Calculated: Short Term 515.0k + Long Term 30.6m)
Net Debt = -25.4m USD (from netDebt column, last quarter)
Enterprise Value = 154.4m USD (223.2m + Debt 31.1m - CCE 99.8m)
Interest Coverage Ratio = -13.91 (Ebit TTM -57.0m / Interest Expense TTM 4.09m)
FCF Yield = -13.08% (FCF TTM -20.2m / Enterprise Value 154.4m)
FCF Margin = -120.3% (FCF TTM -20.2m / Revenue TTM 16.8m)
Net Margin = -802.0% (Net Income TTM -134.7m / Revenue TTM 16.8m)
Gross Margin = 24.18% ((Revenue TTM 16.8m - Cost of Revenue TTM 12.7m) / Revenue TTM)
Tobins Q-Ratio = -0.17 (set to none) (Enterprise Value 154.4m / Book Value Of Equity -932.9m)
Interest Expense / Debt = 13.17% (Interest Expense 4.09m / Debt 31.1m)
Taxrate = 21.0% (US default)
NOPAT = -57.0m (EBIT -57.0m, no tax applied on loss)
Current Ratio = 3.88 (Total Current Assets 104.2m / Total Current Liabilities 26.8m)
Debt / Equity = 0.24 (Debt 31.1m / last Quarter total Stockholder Equity 131.7m)
Debt / EBITDA = -0.55 (Net Debt -25.4m / EBITDA -56.3m)
Debt / FCF = -1.54 (Debt 31.1m / FCF TTM -20.2m)
Total Stockholder Equity = 140.4m (last 4 quarters mean)
RoA = -71.19% (Net Income -134.7m, Total Assets 189.1m )
RoE = -95.92% (Net Income TTM -134.7m / Total Stockholder Equity 140.4m)
RoCE = -33.32% (Ebit -57.0m / (Equity 140.4m + L.T.Debt 30.6m))
RoIC = -40.57% (NOPAT -57.0m / Invested Capital 140.4m)
WACC = 8.72% (E(223.2m)/V(254.2m) * Re(8.49%)) + (D(31.1m)/V(254.2m) * Rd(13.17%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 5.69%
Discount Rate = 8.49% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -20.2m)
EPS Correlation: 15.70 | EPS CAGR: 7.84% | SUE: 0.04 | # QB: 0
Revenue Correlation: -46.31 | Revenue CAGR: -57.77% | SUE: N/A | # QB: None
Additional Sources for ACRS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle